These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 7437842)

  • 1. Drug famine: possible solutions.
    Smith T
    Br Med J; 1980 Nov; 281(6253):1475-7. PubMed ID: 7437842
    [No Abstract]   [Full Text] [Related]  

  • 2. Are the drug-regulatory agencies paper villains?
    Smith T
    Br Med J; 1980 Nov; 281(6251):1333-5. PubMed ID: 7002251
    [No Abstract]   [Full Text] [Related]  

  • 3. Problems raised by the withdrawal from the market of drugs in therapeutic use.
    Lechat P
    Therapie; 1987; 42(4):403-10. PubMed ID: 2961102
    [No Abstract]   [Full Text] [Related]  

  • 4. The emerging effects of the Drug Price Competition and Patent Term Restoration Act of 1984.
    Lewis RA
    J Contemp Health Law Policy; 1992; 8():361-78. PubMed ID: 10118987
    [No Abstract]   [Full Text] [Related]  

  • 5. Replace pharmaceutical patents now.
    Grinols EL; Henderson JW
    Pharmacoeconomics; 2007; 25(5):355-63. PubMed ID: 17488135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patent highlights October-November 2017.
    Mucke HA
    Pharm Pat Anal; 2018 Mar; 7(2):73-81. PubMed ID: 29417883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Experimental product testing of biomedicines].
    Vieths S; Seitz R
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Oct; 57(10):1131-2. PubMed ID: 25200486
    [No Abstract]   [Full Text] [Related]  

  • 8. Biologicals: new horizons in pharmaceutical development.
    Oldham RK
    J Biol Response Mod; 1983; 2(3):199-206. PubMed ID: 6358418
    [No Abstract]   [Full Text] [Related]  

  • 9. Patents: a threat to innovation?
    Manocaran M
    Science; 2010 Jan; 327(5961):31-2; author reply 32. PubMed ID: 20044557
    [No Abstract]   [Full Text] [Related]  

  • 10. The interaction between intellectual property and drug regulatory systems: global perspectives.
    Madden EA
    IDrugs; 2007 Feb; 10(2):116-20. PubMed ID: 17285464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. "NIH-money-for-drug-patent-life" proposal rejected.
    Fox JL
    Nat Biotechnol; 1997 Dec; 15(13):1338. PubMed ID: 9415880
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmaceuticals, patents, publicity...and philanthropy?
    Lancet; 2009 Feb; 373(9665):693. PubMed ID: 19249610
    [No Abstract]   [Full Text] [Related]  

  • 13. 13th EGA annual conference. Challenges in the European and global environment for the generic medicines industry.
    Kuhrt K
    IDrugs; 2007 Aug; 10(8):549-53. PubMed ID: 17665329
    [No Abstract]   [Full Text] [Related]  

  • 14. Democrats on drugs.
    Lancet; 2007 Jan; 369(9556):79. PubMed ID: 17223448
    [No Abstract]   [Full Text] [Related]  

  • 15. Drug costs threaten patent protection.
    Cimons M
    Nat Med; 2003 Jan; 9(1):9. PubMed ID: 12514706
    [No Abstract]   [Full Text] [Related]  

  • 16. US policy may encourage counterfeit drugs.
    Bouchie A
    Nat Biotechnol; 2003 Feb; 21(2):121. PubMed ID: 12560826
    [No Abstract]   [Full Text] [Related]  

  • 17. Brand-name drug companies fail to meet R&D commitments.
    Kondro W
    CMAJ; 2006 Aug; 175(4):344. PubMed ID: 16908891
    [No Abstract]   [Full Text] [Related]  

  • 18. Concept of biosimilar products in Jordan.
    Haddadin RD
    Biologicals; 2011 Sep; 39(5):333-5. PubMed ID: 21873079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A generic problem.
    Hanauer SB
    Nat Clin Pract Gastroenterol Hepatol; 2006 Dec; 3(12):649. PubMed ID: 17130869
    [No Abstract]   [Full Text] [Related]  

  • 20. Biotech patents-business as usual?
    Lawrence S
    Nat Biotechnol; 2008 Dec; 26(12):1326. PubMed ID: 19060861
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.